Expansion Footprint Curia is actively expanding manufacturing and development capabilities with recent facility expansions in Glasgow, UK and Albuquerque, US, signaling increased capacity for drug product and cell line development services and potential to support larger customer programs.

Integrated Service Range With end-to-end offerings from discovery through commercialization and integrated regulatory and analytical capabilities across biologics and small molecules, Curia can position as a single vendor for end-to-end CDMO needs, reducing client vendor fragmentation.

Regulatory & Quality Focus Integrated regulatory and analytical capabilities coupled with a long track record in manufacturing complex modalities suggest Curia can win programs requiring stringent regulatory pathways and robust quality systems, especially for global filings.

Strategic Partnerships A global network of 25 sites and 3,500 employees creates opportunities to propose multi-site development and manufacturing programs, enabling geographic reach for global patients and diversified supply security for sponsors.

Industry Recognition & Stability Recent industry accolades such as regional manufacturing awards and significant capital investments indicate market credibility and growth momentum, which can be leveraged in outreach to risk-averse customers seeking proven CDMOs.